Abstracts tagged "methotrexate (MTX)"

Abstract Number: 2367 • 2014 ACR/ARHP Annual Meeting
Physician Awareness of Suboptimal Patient Adherence to MTX: Results from a Large U.S. Rheumatoid Arthritis Registry
Jeffrey R. Curtis¹, Aseem Bharat², Lang Chen³, Jeffrey D. Greenberg⁴, Joel M. Kremer⁵ and Dimitrios A. Pappas⁴, ¹Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Most rheumatoid arthritis (RA) registries capture information about medication use using data captured at office visits. The extent to which this information may be…
Abstract Number: 1981 • 2014 ACR/ARHP Annual Meeting
A Qualitative Analysis of Methotrexate Injection Videos on Youtube
Rebekah Rittberg¹, Tharindri Dissanayake² and Steven J. Katz³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Rheumatology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Methotrexate (MTX) is one of the most commonly prescribed disease modifying antirheumatic drugs for rheumatoid arthritis. While data suggests subcutaneously administered methotrexate is more…
Abstract Number: 1847 • 2014 ACR/ARHP Annual Meeting
Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose Previous studies evaluating various treatment strategies indicate that disease duration is a key determinant of outcomes in rheumatoid arthritis (RA). While data suggest that…
Abstract Number: 1528 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies
Ronald van Vollenhoven¹, S. B. Cohen², Philip J. Mease³, Charles G. Peterfy⁴, Wolfgang Spieler⁵, Judith Boice⁶, Sean Curtis⁷, Qing Li⁷, Ruji Yao⁸, Richard Baumgartner⁷ and Holly Weng⁸, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Metroplex Clinical Research Center, Dallas, TX, ³University of Washington, Seattle, WA, ⁴Spire Sciences LLC, Boca Raton, FL, ⁵Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁶Merck Research Laboratories, Whitehouse Station, NJ, ⁷Merck & Co., Inc, Whitehouse Station, NJ, ⁸Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Novel, targeted small-molecular medications are needed in the treatment of rheumatoid arthritis (RA). MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK)…
Abstract Number: 1489 • 2014 ACR/ARHP Annual Meeting
Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-
Yuji Hirano¹, Toshihisa Kojima², Yasuhide Kanayama³, Shinya Hirabara¹, Nobunori Takahashi², Atsushi Kaneko⁴ and Naoki Ishiguro², ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan
Background/Purpose: Iguratimod (IGU), known as T-614, is a small-molecule antirheumatic drug developed in Japan and used in Japanese clinical practice since June in 2012. IGU…
Abstract Number: 1360 • 2014 ACR/ARHP Annual Meeting
Monitoring Methotrexate and Leflunomide Treatment for Liver Toxicity: the Kaiser Permanente Experience
Robert Goldfien¹ and Lisa Herrinton², ¹Rheumatology, Kaiser Permanente, Richmond, CA, ²Division of Research, Kaiser Permanente, Oakland, CA
Background/Purpose: Methotrexate (MTX) and Leflunomide (LEF) are widely prescribed to treat rheumatologic and other diseases. Each has the potential to cause liver injury in some…
Abstract Number: 3010 • 2014 ACR/ARHP Annual Meeting
The Development and Evaluation of a Self-Monitoring and Patient-Initiated Follow-up Service for People with Rheumatoid or Psoriatic Arthritis on Methotrexate
Hayley McBain^1,2, Michael Shipley³, Abigail Olaleye³, Samantha Moore⁴, Shashi Hirani⁵ and Stanton Newman⁶, ¹Health Services Research and Management Division, City University London, London, United Kingdom, ²Community Health Newham, East London Foundation Trust, London, United Kingdom, ³University College Hospital London, London, United Kingdom, ⁴Rheumatology, University College London, London, United Kingdom, ⁵City University London, London, United Kingdom, ⁶School of Community & Health Sciences, City University London, London, United Kingdom
Background/Purpose: Patient-initiated services in rheumatology have been found to be cost-saving without compromising the clinical or psychosocial well-being of patients with rheumatoid arthritis. Self-monitoring is…
Abstract Number: 516 • 2014 ACR/ARHP Annual Meeting
The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study
Shinya Hirabara¹, Toshihisa Kojima², Nobunori Takahashi², Yuji Hirano¹, Atsushi Kaneko³, Daihei Kida⁴, Yasuhide Kanayama⁵ and Naoki Ishiguro², ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, ⁵Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often…
Abstract Number: 2925 • 2014 ACR/ARHP Annual Meeting
Serum MMP-3 Predicts a Subgroup with No Radiographic Progression in Rheumatoid Arthritis Patients with Low-Dose Methotrexate (MTX) Monotherapy
Kazuko Shiozawa¹, Takashi Yamane², Miki Murata¹, Chihiro Tanaka¹, Noriaki Yo², Ryosuke Yoshihara¹, Yasushi Tanaka¹, Ken Tsumiyama³ and Shunichi Shiozawa⁴, ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Kohnan Kakogawa Hospital, Kakogawa, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Studies have shown that treating rheumatoid patients with methotrexate (MTX) monotherapy initially and later providing an option to step up to combination therapy produces…
Abstract Number: 512 • 2014 ACR/ARHP Annual Meeting
Effect and Safety of Concomitant Methotrexate and Tacrolimus on Clinical Response of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Biological Dmards
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT) is a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to…
Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Josef Smolen¹, Ronald F. van Vollenhoven², Stefan Florentinus³, Yijie Zhou⁴, Benoit Guerette⁴ and Arthur Kavanaugh⁵, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³AbbVie, Rungis, France, ⁴AbbVie, Inc., North Chicago, IL, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…
Abstract Number: 514 • 2014 ACR/ARHP Annual Meeting
Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Katja Perdan-Pirkmajer¹, Sergej Pirkmajer², Alojzija Hocevar¹, ŽIga Rotar¹, Natasa Gaspersic¹, Sonja Praprotnik¹, Matija Tomsic³ and Ales Ambrozic¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Institute of Pathophysiology, Faculty of Medicine Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with an increased risk of diabetes mellitus (DM). Disease-modifying anti-rheumatic drugs, including methotrexate (MTX), may…
Abstract Number: 2504 • 2014 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT), a selective co-stimulation modulator, is the first in a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that…
Abstract Number: 496 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Induction Therapy for Rheumatoid Arthritis with Simultaneous Administration of Methotrexate and Low-Dose Tacrolimus: A Retrospective Study
Takashi Nakanishi¹, Hideyuki Horikoshi¹, Reiko Takahashi¹, Kanami Tongu², Junko Nishioka², Fumihiko Kimura³, Yuichi Nishioka² and Kenji Itoh¹, ¹Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, ²Nishioka Clinic for Rheumatic Diseases and Allergic Diseases, Kofu, Japan, ³National Defense Medical College, Tokorozawa, Japan
Background/Purpose Additional administration of low-dose tacrolimus (LD-TAC) at 0.5–1.0 mg daily was reported to be quite effective for rheumatoid arthritis (RA) patients with inadequate response…
Abstract Number: 2767 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ariella Kelman⁶, Sophie Dimonaco⁷ and Nina Mitchell⁷, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Genentech, South San Francisco, CA, ⁷Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Recent recommendations support intensive treatment of patients (pts) with early rheumatoid arthritis (RA) to achieve remission or low disease activity.1-3 Tocilizumab (TCZ) was not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].